

8-20-07

15w

**IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE**

Serial No. : 10/525,986
Applicants : Tadashi NAKAJIMA et al.
Filed : February 25, 2005
For : THERAPEUTIC AGENT FOR
GLAUCOMA COMPRISING Rho
KINASE INHIBITOR AND
PROSTAGLANDIN
All Unit : 1618
Examiner : Zohreh FAY
Docket No. : 05116/HG
Confirm No. : 5004
Customer No.: 01933



Express Mail Mailing Label
No.: EM 155 716 583 US
Date of Deposit: August 16, 2007
I hereby certify that this paper is
being deposited with the United States
Postal Service "Express Mail Post
Office to Addressee" service under
37 CFR 1.10 with sufficient postage
on the date indicated above and is
addressed to:
MAIL STOP AMENDMENT
Commissioner for Patents,
P.O. Box 1450
Alexandria, VA 22313-1450

Dorothy DeFrancesco
Dorothy DeFrancesco

In the event that this Paper is late
filed, and the necessary petition
for extension of time is not filed
concurrently herewith, please consider
this as a Petition for the requisite
extension of time, and to the extent
not tendered by Form PTO-2038 attached
hereto, authorization to charge the
extension fee, or any other fee
required in connection with this
Paper to Account No. 06-1378.

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

MAIL STOP AMENDMENT

S I R :

Submitted concomitantly herewith are the following:

- (1) A copy of a Supplementary Partial European Search
Report, which issued in the counterpart European application;
- (2) IDS Forms. It is respectfully requested that initialed
copies of the enclosed IDS Forms be returned to the undersigned
to indicate that the publications listed therein have been
considered and made of record; and

(3) Copies of the non-U.S. patent documents cited in said IDS Forms.

Each of the cited publications, which are disclosed in the enclosed Search Report, is considered relevant or material to the patentability of the present claims in view of the citation thereof in said Search Report.

Said Search Report is in English, thereby satisfying the requirements for a concise explanation of relevance for the publications cited therein.

The following publication, which was cited in the enclosed Supplementary Partial European Search Report, was cited in the INFORMATION DISCLOSURE STATEMENT dated May 16, 2005:

HONJO MEGUMI et al., "Effects of Rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility," Investigative Ophthalmology & Visual Science, Association for Research in Vision, Vol. 42, No. 1, January 2001, pp. 137-144.

The following is a copending related application: Serial No. 10/535,000 (published as US 2006/0052367).

The enclosed IDS Forms include publications cited in
application Serial No. 10/535,000.

Respectfully submitted,



RICHARD S. BARTH
REG. NO. 28,180

FRISHAUF, HOLTZ, GOODMAN & CHICK, P.C.
220 FIFTH AVENUE, 16th FLOOR
NEW YORK, NEW YORK 10001-7708
Tel. Nos. (212) 319-4900
(212) 319-4551/Ext. 219
Fax No. (212) 319-5101
E-Mail Address: BARTH@FHGC-LAW.COM
RSB/ddf

- Encs.: (1) copy of Supplementary Partial European Search Report
dated June 6, 2007
- (2) IDS Forms
- (3) copies of the non-U.S. patent documents cited on the
enclosed IDS Forms


Please type a plus sign (+) inside this box →

+

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

IDS FORM

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT



Application Number	10/525,986
Filing Date	February 25, 2005
First Named Inventor	Tadashi NAKAJIMA
Group Art Unit	1618
Examiner Name	Zohreh FAY
Attorney Docket Number	05116/HG

Sheet

1

of

3

U.S. PATENT DOCUMENTS

Exam. Inits ¹	Cite No ¹	Document Number	Kind Code ²	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion
		2006/0052367	A1	HATANO et al.	03-09-2006	

FOREIGN PATENT DOCUMENTS

Exam. Inits ¹	Cite No ¹	Offc ³	Document Number ⁴	Kind Code ⁵	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion	T ⁶
		WO	00/25771	A1	SYNPHORA AB	05-11-2000		
		WO	00/57914	A1	SANTEN PHARMACEUTICAL CO LTD	10-05-2000		a
		WO	93/16701	A2	ALCON LABORATORIES INC	09-02-1993		
		WO	03/049745	A1	PHARAMCIA CORP	06-19-2003		

Examiner
Signature

Date
Considered

* EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Place a check here if English translation is attached.

DATE: August 16, 2007

a ENGLISH-LANGUAGE ABSTRACT ENCLOSED

Please type a plus sign (+) inside this box →



U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

IDS FORM INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/525,986
				Filing Date	February 25, 2005
				First Named Inventor	Tadashi NAKAJIMA
				Group Art Unit	1618
				Examiner Name	Zohren FAY
Sheet	2	of	3	Attorney Docket Number	05116/HG

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		<p>ZHOU YAN et al., "Nonsteroidal Anti-Inflammatory Drugs Can Lower Amyloidogenic Aβ₄₂ by Inhibiting Rho," <u>Science</u>, Vol. 302, no. 5648, 14 November 2003, pp. 1215-1217</p> <p>HONJO et al., "Effects of Protein Kinase Inhibitor, HA1077, on Intraocular Pressure and Outflow Facility in Rabbit Eyes," <u>Archives of Ophthalmology</u>, Vol. 119, no. 8, August 2001, pp. 1171-1178</p> <p>DATABASE WPI Week 200060, Derwent Publications ltd., London, GB; AN 2000-628321 of WO 00/57914 (Santen Pharmaceutical Co., Ltd.; Oct. 5, 2002)</p> <p>CLARK A.F. et al., "Advances in Glaucoma Therapeutics," <u>Expert Opinion of Emerging Drugs</u>, 2002, United Kingdom, Vol. 7, no. 1, May 2002, pp. 141-163</p> <p>UEHATA M. et al., "Calcium Sensitization of Smooth Muscle Mediated by a Rho-Associated Protein Kinase in Hypertension," <u>Nature</u>, Vol. 389, October 1997, pp. 990-994</p> <p>Mariko ASahi et al., "Ryokunaisho to Ryokunaisho Chiryo Yakuzai (Fukuyaki Shido Manual II, Dai 10 Kai)," <u>The Pharmaceuticals Monthly</u>, (1996), 38(9), pp. 2311 to 2331</p> <p>Kuniteru SHIRATO, "I. Ryokunaisho no Yakubutsu Ryoho 1. Gairon" (Chiryoyaku no Sentaku o Dou Kangaerunoka), ("Some Practical Aspect in Medical Therapy") Ganka, (2002), 44(11), pp. 1443 to 1448</p> <p>Tatsuro FUKUCHI, "I. Ryokunaisho no Yakubutsu Ryoho 2. Ryokunaisho Chiryoyaku C. Kokan Shinkei Sogaiyaku β Shadanyaku," ("β-Adrenergic Antagonists") Ganka, (2002), 44(11), pp. 1458 to 1463</p> <p>Yuichiro OTAKE et al., "Effect and Safety of Combined Therapy with Betaxolol and isopropyl Unoprostone," <u>The Journal of the Eye</u>, (2000), 17(5), pp. 687 to 690</p>	
Examiner Signature		Date Considered	

* EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Place a check here if English translation is attached.

DATE: August 16, 2007

Please type a plus sign (+) inside this box →



U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

IDS FORM INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/525,986
				Filing Date	February 25, 2005
				First Named Inventor	Tadashi NAKAJIMA
				Group Art Unit	1618
				Examiner Name	Zohreh FAY
Sheet	3	of	3	Attorney Docket Number	05116/HG

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		<p>Hideki TOKUSHIGE, "ROCK Sogaiyaku to Ryokunaisho" ("ROCK Inhibitor and Glaucoma"), <u>BIO Clinica</u>, (2002), 17(13), pp. 1191 to 1194.</p> <p>HOYNG, P.F.J. et al., "Pharmacological Therapy for Glaucoma," <u>Drugs</u>, (2000), 59(3), pp. 411 to 434.</p> <p>Ikuo AZUMA et al., "Effects of Bunazosin Hydrochloride Ophthalmic Solution in Combination with Timolol Maleate Ophthalmic Solution in Patients with Open-Angle Glaucoma and Ocular Hypertension-Comparison with Dipivefrin Hydrochloride Ophthalmic Solution," <u>The Journal of the Eye</u>, (2002), 1992), pp. 261-266</p> <p>Marie A. ABATE et al., "Effect of Naproxen and Sulindac on Blood Pressure Response to Atenolol," <u>DICP - ANNALS OF PHARMACOTHERAPY</u>, Vol. 24, no. 9, 1990, pp. 810-813</p>	
Examiner Signature		Date Considered	

* EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Place a check here if English translation is attached.

DATE: August 16, 2007